Launching a new medicine, particularly in the EU, requires an in-depth understanding of the impact of declaring a price in early-launch markets on pricing in subsequent markets; optimal handling of this chain of events will protect initial product pricing.

Medialis has experience in the design of launch sequences for new medicinal products and can tailor our approach to the specific requirements of each client.